4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $29.8750.

Several equities research analysts have weighed in on the company. Chardan Capital reissued a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Jefferies Financial Group restated a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday, March 30th. Royal Bank Of Canada increased their price objective on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th.

4D Molecular Therapeutics Trading Down 6.0%

NASDAQ FDMT opened at $8.67 on Wednesday. The firm’s fifty day simple moving average is $9.46 and its two-hundred day simple moving average is $9.15. The firm has a market capitalization of $453.27 million, a P/E ratio of -3.37 and a beta of 2.75. 4D Molecular Therapeutics has a 12-month low of $3.68 and a 12-month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The business had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $2.59 million. As a group, sell-side analysts predict that 4D Molecular Therapeutics will post -3.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FDMT. Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics in the first quarter valued at about $39,000. Wexford Capital LP acquired a new position in 4D Molecular Therapeutics in the 3rd quarter worth approximately $41,000. AQR Capital Management LLC acquired a new position in 4D Molecular Therapeutics in the 1st quarter worth approximately $46,000. Daiwa Securities Group Inc. raised its position in 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after buying an additional 6,186 shares during the last quarter. Finally, Rangeley Capital LLC purchased a new position in 4D Molecular Therapeutics during the 2nd quarter worth approximately $48,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.